SBI Okasan Asset Management Co.Ltd. Takes $638,000 Position in Xenon Pharmaceuticals Inc. $XENE

SBI Okasan Asset Management Co.Ltd. acquired a new stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) in the fourth quarter, HoldingsChannel reports. The institutional investor acquired 14,400 shares of the biopharmaceutical company’s stock, valued at approximately $638,000.

A number of other hedge funds also recently made changes to their positions in the business. Wellington Management Group LLP raised its stake in shares of Xenon Pharmaceuticals by 66.0% in the 3rd quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company’s stock valued at $144,936,000 after buying an additional 1,435,096 shares in the last quarter. Commodore Capital LP raised its stake in shares of Xenon Pharmaceuticals by 30.1% in the 2nd quarter. Commodore Capital LP now owns 3,025,000 shares of the biopharmaceutical company’s stock valued at $94,682,000 after buying an additional 700,000 shares in the last quarter. Vestal Point Capital LP raised its stake in shares of Xenon Pharmaceuticals by 53.8% in the 2nd quarter. Vestal Point Capital LP now owns 2,000,000 shares of the biopharmaceutical company’s stock valued at $62,600,000 after buying an additional 700,000 shares in the last quarter. Holocene Advisors LP raised its stake in shares of Xenon Pharmaceuticals by 9.2% in the 3rd quarter. Holocene Advisors LP now owns 1,976,553 shares of the biopharmaceutical company’s stock valued at $79,359,000 after buying an additional 167,078 shares in the last quarter. Finally, Alliancebernstein L.P. raised its stake in shares of Xenon Pharmaceuticals by 8.9% in the 3rd quarter. Alliancebernstein L.P. now owns 1,654,417 shares of the biopharmaceutical company’s stock valued at $66,425,000 after buying an additional 135,890 shares in the last quarter. Institutional investors and hedge funds own 95.45% of the company’s stock.

Xenon Pharmaceuticals Stock Performance

XENE opened at $54.73 on Friday. The firm’s 50-day simple moving average is $56.02 and its 200-day simple moving average is $48.10. Xenon Pharmaceuticals Inc. has a twelve month low of $28.19 and a twelve month high of $63.95. The firm has a market cap of $5.29 billion, a price-to-earnings ratio of -11.64 and a beta of 0.65.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, hitting the consensus estimate of ($1.17). During the same quarter in the prior year, the business posted ($0.83) earnings per share. As a group, sell-side analysts anticipate that Xenon Pharmaceuticals Inc. will post -4.88 EPS for the current fiscal year.

Analysts Set New Price Targets

XENE has been the subject of a number of recent research reports. JPMorgan Chase & Co. increased their price objective on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “overweight” rating in a research note on Wednesday. Morgan Stanley set a $97.00 price objective on shares of Xenon Pharmaceuticals in a research note on Monday, March 9th. Guggenheim restated a “buy” rating and issued a $90.00 price objective on shares of Xenon Pharmaceuticals in a research note on Monday, March 9th. Needham & Company LLC dropped their price objective on shares of Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating for the company in a research note on Friday, May 8th. Finally, Wolfe Research started coverage on shares of Xenon Pharmaceuticals in a report on Monday, February 23rd. They issued an “outperform” rating and a $60.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Xenon Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $77.20.

Insider Buying and Selling at Xenon Pharmaceuticals

In other Xenon Pharmaceuticals news, insider Christopher John Kenney sold 1,410 shares of the firm’s stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $55.23, for a total value of $77,874.30. Following the completion of the sale, the insider owned 7,069 shares in the company, valued at approximately $390,420.87. This trade represents a 16.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Ian Mortimer sold 7,308 shares of the firm’s stock in a transaction dated Friday, March 13th. The shares were sold at an average price of $55.23, for a total transaction of $403,620.84. Following the completion of the sale, the chief executive officer owned 19,923 shares of the company’s stock, valued at $1,100,347.29. The trade was a 26.84% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 296,707 shares of company stock worth $17,845,365. 4.07% of the stock is currently owned by corporate insiders.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.